Relapsed Refractory Multiple Myeloma clinical trials

Explore recruiting relapsed refractory multiple myeloma clinical trials.

Recruiting relapsed refractory multiple myeloma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed Refractory Multiple Myeloma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1/2 Study of Etentamig in Combination with a CELMoD Agent for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma

France, Norway, Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase I/IIa Study of ODX (OsteoDex) in Multiple Myeloma

Sweden

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone (B-Pd) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) in Participants with Relapsed/Refractory Multiple Myeloma (DREAMM 8)

Czechia, Greece, Germany, Poland, France, Italy +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Combination treatment of Belantamab Mafodotin and Venetoclax in treatment of relapsed and refractory t(11;14) Multiple Myeloma (Phase I/IIa) _ The BELI(E)VE-Trial

Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants with Relapsed/Refractory Multiple Myeloma

Spain, Czechia, Germany, Netherlands, Belgium, Poland +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib And Dexamethasone (MeziVd) Versus Pomalidomide, Bortezomib And Dexamethasone (PVd) In Subjects With Relapsed Or Refractory Multiple Myeloma (RRMM): Successor-1

Ireland, Portugal, Greece, France, Czechia, Romania +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Relapsed Refractory Multiple Myeloma trials by city

Relapsed Refractory Multiple Myeloma in Toronto Relapsed Refractory Multiple Myeloma in Vancouver Relapsed Refractory Multiple Myeloma in Montreal Relapsed Refractory Multiple Myeloma in Calgary Relapsed Refractory Multiple Myeloma in Edmonton Relapsed Refractory Multiple Myeloma in Ottawa Relapsed Refractory Multiple Myeloma in Winnipeg Relapsed Refractory Multiple Myeloma in Quebec City Relapsed Refractory Multiple Myeloma in Hamilton Relapsed Refractory Multiple Myeloma in Kitchener Relapsed Refractory Multiple Myeloma in London Relapsed Refractory Multiple Myeloma in Halifax Relapsed Refractory Multiple Myeloma in New York Relapsed Refractory Multiple Myeloma in Los Angeles Relapsed Refractory Multiple Myeloma in Chicago Relapsed Refractory Multiple Myeloma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease